BACKGROUND: Understanding the natural history of non-malignant peripheral nerve sheath tumors (PNSTs) in neurofibromatosis type 1 (NF1) is critical to optimal clinical care and the development of meaningful clinical trials. METHODS: We longitudinally analyzed growth of plexiform neurofibromas (PNs) and of PNSTs with distinct nodular appearance (distinct nodular lesions [DNLs]) using volumetric MRI analysis in patients enrolled on a natural history study (NCT00924196). RESULTS: DNLs were observed in 58/122 (45.6%) patients (median 2 DNLs/patient). In DNLs that developed during follow-up, median age of development was 17 years. A moderate negative correlation was observed between the estimated PN growth rate and patients' age at initial MRI (Spearman's r [95% CI]: -0.60 [-0.73, -0.43], n = 70), whereas only a weak correlation was observed for DNLs (Spearman's r [95% CI]: -0.25 [-0.47, 0.004]; n = 61). We observed a moderate negative correlation between tumor growth rate and baseline tumor volume for PNs and DNLs (Spearman's r [95% CI]: -0.52 [-0.67, -0.32] and -0.61 [-0.75, -0.42], respectively). Spontaneous tumor volume reduction was observed in 10 PNs and 7 DNLs (median decrease per year, 3.6% and 7.3%, respectively). CONCLUSION: We corroborate previously described findings that most rapidly growing PNs are observed in young children. DNLs tend to develop later in life and their growth is minimally age related. Distinct growth characteristics of PNs and DNLs suggest that these lesions have a different biology and may require different clinical management and clinical trial design. In a subset of PNs and DNLs, slow spontaneous regression in tumor volume was seen. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2020.
BACKGROUND: Understanding the natural history of non-malignant peripheral nerve sheath tumors (PNSTs) in neurofibromatosis type 1 (NF1) is critical to optimal clinical care and the development of meaningful clinical trials. METHODS: We longitudinally analyzed growth of plexiform neurofibromas (PNs) and of PNSTs with distinct nodular appearance (distinct nodular lesions [DNLs]) using volumetric MRI analysis in patients enrolled on a natural history study (NCT00924196). RESULTS: DNLs were observed in 58/122 (45.6%) patients (median 2 DNLs/patient). In DNLs that developed during follow-up, median age of development was 17 years. A moderate negative correlation was observed between the estimated PN growth rate and patients' age at initial MRI (Spearman's r [95% CI]: -0.60 [-0.73, -0.43], n = 70), whereas only a weak correlation was observed for DNLs (Spearman's r [95% CI]: -0.25 [-0.47, 0.004]; n = 61). We observed a moderate negative correlation between tumor growth rate and baseline tumor volume for PNs and DNLs (Spearman's r [95% CI]: -0.52 [-0.67, -0.32] and -0.61 [-0.75, -0.42], respectively). Spontaneous tumor volume reduction was observed in 10 PNs and 7 DNLs (median decrease per year, 3.6% and 7.3%, respectively). CONCLUSION: We corroborate previously described findings that most rapidly growing PNs are observed in young children. DNLs tend to develop later in life and their growth is minimally age related. Distinct growth characteristics of PNs and DNLs suggest that these lesions have a different biology and may require different clinical management and clinical trial design. In a subset of PNs and DNLs, slow spontaneous regression in tumor volume was seen. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2020.
Authors: Christine S Higham; Eva Dombi; Aljosja Rogiers; Sucharita Bhaumik; Steven Pans; Steve E J Connor; Markku Miettinen; Raf Sciot; Roberto Tirabosco; Hilde Brems; Andrea Baldwin; Eric Legius; Brigitte C Widemann; Rosalie E Ferner Journal: Neuro Oncol Date: 2018-05-18 Impact factor: 12.300
Authors: Elina Uusitalo; Matti Rantanen; Roope A Kallionpää; Minna Pöyhönen; Jussi Leppävirta; Heli Ylä-Outinen; Vincent M Riccardi; Eero Pukkala; Janne Pitkäniemi; Sirkku Peltonen; Juha Peltonen Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544
Authors: Eline Beert; Hilde Brems; Bruno Daniëls; Ivo De Wever; Frank Van Calenbergh; Joseph Schoenaers; Maria Debiec-Rychter; Olivier Gevaert; Thomas De Raedt; Annick Van Den Bruel; Thomy de Ravel; Karen Cichowski; Lan Kluwe; Victor Mautner; Raf Sciot; Eric Legius Journal: Genes Chromosomes Cancer Date: 2011-08-24 Impact factor: 5.006
Authors: E Dombi; J Solomon; A J Gillespie; E Fox; F M Balis; N Patronas; B R Korf; D Babovic-Vuksanovic; R J Packer; J Belasco; S Goldman; R Jakacki; M Kieran; S M Steinberg; B C Widemann Journal: Neurology Date: 2007-01-10 Impact factor: 9.910
Authors: Markku M Miettinen; Cristina R Antonescu; Christopher D M Fletcher; Aerang Kim; Alexander J Lazar; Martha M Quezado; Karlyne M Reilly; Anat Stemmer-Rachamimov; Douglas R Stewart; David Viskochil; Brigitte Widemann; Arie Perry Journal: Hum Pathol Date: 2017-05-24 Impact factor: 3.466
Authors: Carlos E Prada; Fatima A Rangwala; Lisa J Martin; Anne M Lovell; Howard M Saal; Elizabeth K Schorry; Robert J Hopkin Journal: J Pediatr Date: 2011-10-11 Impact factor: 4.406
Authors: Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann Journal: N Engl J Med Date: 2016-12-29 Impact factor: 91.245
Authors: Victor-F Mautner; Florence A Asuagbor; Eva Dombi; Carsten Fünsterer; Lan Kluwe; Ralf Wenzel; Brigitte C Widemann; Jan M Friedman Journal: Neuro Oncol Date: 2008-06-17 Impact factor: 12.300
Authors: Lennart Well; Kimberly Döbel; Lan Kluwe; Peter Bannas; Said Farschtschi; Gerhard Adam; Victor-Felix Mautner; Johannes Salamon Journal: PLoS Genet Date: 2021-05-05 Impact factor: 5.917
Authors: Caitlin Tydings; Pavel Yarmolenko; Miriam Bornhorst; Eva Dombi; John Myseros; Robert Keating; James Bost; Karun Sharma; AeRang Kim Journal: Neurooncol Adv Date: 2021-08-18
Authors: Jeffrey J Szymanski; R Taylor Sundby; Paul A Jones; Divya Srihari; Noah Earland; Peter K Harris; Wenjia Feng; Faridi Qaium; Haiyan Lei; David Roberts; Michele Landeau; Jamie Bell; Yi Huang; Leah Hoffman; Melissa Spencer; Matthew B Spraker; Li Ding; Brigitte C Widemann; Jack F Shern; Angela C Hirbe; Aadel A Chaudhuri Journal: PLoS Med Date: 2021-08-31 Impact factor: 11.069